There are few long-term nationally representative studies of all-cause mortality among those infected with hepatitis C virus (HCV). When an additional 5 years of data were made publicly available in 2015, the Third National Health and Nutrition Examination Survey Linked Mortality File became the longest nationally representative study in the United States. Our objective was to update the estimated HCV-associated all-cause mortality in the general US population and determine any differences by sex, age and race/ethnicity. HCV status was assessed in 9117 nationally representative adults aged 18-59 years from 1988 to 1994, and mortality follow-up of the same individuals was completed through 2011 and made publicly available in 2015. There were 930 deaths over a median follow-up of 19.8 years. After adjusting for all covariate risk factors, chronic HCV had 2.63 times (95% CI: 1.59-4.37; P=.0002) higher all-cause mortality rate ratio (MRR) compared with being HCV negative. All-cause MRR was stratified by sex, age and race/ethnicity. Only race/ethnicity was a significant effect modifier of MRR (P<.0001) as the highest MRR of chronic HCV compared to HCV negative was 7.48 (95% CI: 2.15-26.10, P=.001) among Mexican Americans, 2.67 (95% CI: 2.67-5.56, P=.009) among non-Hispanic Whites and 2.02 (95% CI: 1.20-3.40, P=.007) among non-Hispanic Blacks. Racial disparity was seen in the all-cause mortality as Mexican Americans with chronic HCV had approximately seven times higher mortality rate than HCV-negative individuals. This suggests that these at-risk individuals should be targeted for HCV screening and treatment, given the availability of new highly effective HCV therapies.
liver transplantation in the USA. 6, 7 By 2007, deaths in the USA due to HCV surpassed HIV. 8 By the end of 2014, oral direct-acting antiviral (DAA) drugs become available, which can completely cure HCV infection in patients by achieving sustained virologic response (SVR). 9 The new DAA drugs have improved tolerability, decreased therapy duration, increased SVR and simplified therapy compared to the firstgeneration therapy based on alpha interferon injections. 9 DAA therapy is expected to reduce future all-cause and liver-related morbidity and mortality. 10, 11 Yet challenges still remain in the USA as the HCV care continuum is failing as only 50% of HCV-infected persons have been tested, only 16% treated and 9% cured. 12, 13 Based on the National Health and Nutrition Examination Survey in the US population also increased from 2.7 to 3.2 million. 14, 15 The mortality follow-up of the Third NHANES (NHANES III) participants through 2006 showed that persons with chronic HCV had 2.4 times higher all-cause, 26.5 times higher liver-related and 1.8 times higher nonliver mortality rate ratios compared to HCV-negative individuals. 16 The rates confirm that individuals with chronic HCV are at higher risk of mortality and show the opportunity for HCV treatment to reduce both long-term morbidity 10 and mortality. 17, 18 In 2015, the publicly available NHANES III mortality follow-up data through the end of 2011 became available providing an additional 5 years of follow-up on mortality. This provides the opportunity to provide a longer follow-up time compared to the previous mortality study and is the last set of all-cause mortality data before the advent of DAA therapy in 2014. In addition, during these additional 5 years of follow-up, the US recession (2006) (2007) (2008) (2009) (2010) (2011) could have exacerbated the effects of HCV on mortality on already vulnerable individuals due to job and health insurance losses, particularly that HCV testing and linkage to care is already suboptimal among racial/ethnic minorities. 19 In this study, we evaluated the association of HCV status with all-cause mortality and determined any differences by sex, age and race/ethnicity in a prospective cohort of NHANES participants that is representative of the noninstitutionalized population of US adults. We aimed to identify individuals at highest risk of mortality for a curable disease and that should help prioritize HCV treatment.
| METHODS

| Study participants
Participants included in the analysis were from NHANES III survey aged ≥18 years at initial enrolment and with vital status follow-up data till the end of 2011. Conducted in 1988-1994 by the National
Center for Health Statistics, NHANES III is a multistage probability survey designed to represent noninstitutionalized American civilians, which oversampled non-Hispanic Blacks, Mexican Americans and older adults. 20, 21 Our initial analysis included all participants ≥18 years with eligibility status for mortality follow-up and HCV antibody test (n=16 140). These participants were subsequently narrowed to only 9117 participants aged 18-59 years for whom HCV covariate risk factor information was available so that additional covariate-adjusted analyses could be performed.
| Study variables
Third National Health and Nutrition Examination Survey includes an interview and physical examination with a blood draw. 20 The procedures for the survey and data collection, 21 This secondary analysis was performed using a de-identified data set. 
| Statistical analysis
| RESULTS
Among 16 and malignant neoplasms (12%). individuals, except among women aged 18-29 years. Anti-HCVnegative men had higher mortality rate than anti-HCV-negative women. However, this pattern was not observed for anti-HCV-positive or chronic HCV individuals as women had higher mortality rates than men (Table 1) .
Among participants aged 18-59 years (n=9117), those who were anti-HCV positive or chronic HCV were more likely to be men, nonHispanic White, nonmarried and current smokers (P<.05) than those who were anti-HCV negative (Table 2) . Those who were anti-HCV negative had higher incomes, fewer sexual partners, less cocaine, marijuana and alcohol use, and lower ALT levels (P<.001).
Among We stratified the MRR for all-cause mortality by race/ethnicity (Table 4) , sex ( (Table 4 ). Figure 1 shows the overall estimated unadjusted and adjusted mortality cumulative incidence (covariates set at survey-weighted means) by HCV status. The mortality cumulative incidence among anti-HCV-positive and chronic HCV-infected participants appears to be increasing at a slower rate during the last
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The association between anti-HCV/HCV RNA status and all-cause mortality among 9117 NHANES III participants aged 18-59 years by age group With additional five years of follow-up data, we expected and observed more deaths with an increase in all-cause mortality rates.
We were surprised to find that women had a higher overall all-cause 29 While our study is restricted to all-cause mortality, we hypothesize for liver-related mortality, Mexican Americans and Hispanics will still have a greater mortality compared to non-Hispanic Whites and non-Hispanic Blacks.
Our study had several strengths including using the large representative sample of US adults selected with no prior knowledge of their HCV status, objectively measured HCV antibody and HCV RNA, long follow-up period through 2011, covariates known to impact mortality in these populations to adjust for confounding factors and validation using multiple analysis techniques. These data precede the marketing of DAAs and therefore provide a general sense of survival in the premodern HCV treatment era. Our study had some limitations that should be noted when interpreting the results.
First, we only had access to the public-use and not the restricted-use linked mortality files to allow specific analyses on both liver-related and non-liver-related causes of death. This limited our ability to compare results with previous findings in this NHANES III cohort and any stratum-specific findings such as race/ethnicity. Second, NHANES III is an observational study and there are potential unmeasured or excluded confounding factors. We cannot rule out the potential for unmeasured confounders, such as genetic variants and other metabolic-related disorders, as a noncausal source of association; however, we have attempted to mitigate this limitation by controlling for multiple known confounders in the analysis with three different models.
In conclusion, this study suggests a racial disparity and an increase in the all-cause mortality by HCV status in the general US population using NHANES III with follow-up through 2011. Our finding indicates effect modification by race/ethnicity as Mexican Americans with chronic HCV had seven times higher mortality rate than HCVnegative individuals in a fully adjusted model for confounding factors.
These findings suggest a need to consider race in the HCV care continuum. Future research is needed to examine whether DAA therapy and changes to health care access to include HCV treatment coverage will translate into population-level changes in overall mortality and by race/ethnic groups.
